Printer Friendly

NEORX RECEIVES FAVORABLE FDA REVIEW LETTER

 NEORX RECEIVES FAVORABLE FDA REVIEW LETTER
 SEATTLE, Jan. 22 /PRNewswire/ -- NeoRx Corporation (NASDAQ: NERX)


announced today that it has received notification from the FDA that it has completed its review of the clinical data filed in NeoRx's Product License Application (PLA) for its OncoTrac(R) small cell lung cancer imaging agent. The PLA was filed in December 1989 and included data that demonstrated that the OncoTrac imaging agent can be administered safely and that it is useful for staging patients with newly diagnosed disease.
 According to Darrell Salk, M.D., NeoRx vice president of medical and regulatory affairs, "The FDA has written to us stating that it sees no issues regarding the clinical utility of the product."
 The NeoRx OncoTrac lung cancer imaging agent is used to detect how far tumors may have spread in patients. In a Phase III study of patients with small cell lung cancer, OncoTrac alone was compared to a diagnostic battery combining four standard imaging procedures. "We believe ours is the only study that has made such a direct comparison and shown that a single test can yield comparable results," stated Dr. Salk.
 NeoRx has also completed a Phase III study using the same product in patients with non-small cell lung cancer. There are approximately 160,000 new cases of lung cancer annually in the U.S. OncoTrac is the only antibody-based imaging agent that has been evaluated in Phase III clinical trials for both small cell and non-small cell lung cancer.
 Two months ago the FDA announced a consensus within the agency on clinical endpoints to be used for monoclonal antibody imaging agents. Commented Dr. Salk, "In light of recent FDA Advisory Committee reviews of other monoclonal antibody-based imaging agents, we are very pleased to have received this notice from the FDA about our clinical results. With resolution of the endpoint issue, it appears that the evaluation of these types of products is now moving forward."
 NeoRx Corporation, incorporated in May 1984, is developing monoclonal antibody-based pharmaceutical products for in vivo detection and treatment of certain types of cancer. The company has three cancer therapy trials in progress and has filed for marketing approval with the FDA for two OncoTrac imaging products to detect metastatic melanoma and small cell lung cancer.
 -0- 1/22/92 R
 /CONTACT: Robert M. Littauer, vice president, chief financial officer and treasurer of NeoRx, 206-286-2519, or Anthony J. Russo, or Susan A. Noonan of Noonan/Russo Communications, 212-979-9180, for NeoRx/
 (NERX) CO: NeoRx Corporation ST: Washington IN: MTC SU:


GK -- NY005R -- 3101 01/22/92 08:38 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 22, 1992
Words:429
Previous Article:THOMASTON MILLS, INC. REPORTS SECOND QUARTER RESULTS OF OPERATIONS
Next Article:CORESTATES FINISHES 1991 WITH SOLID RESULTS; NET IS $1.11 PER SHARE FOR QUARTER, $4.19 FOR YEAR
Topics:


Related Articles
NEORX ANNOUNCES FOURTH QUARTER FINANCIAL RESULTS
NEORX ANNOUNCES FOURTH QUARTER FINANCIAL RESULTS
NEORX RECEIVES $9 MILLION FROM DAVID BLECH
NEORX ANNOUNCES FIRST QUARTER RESULTS FOR FISCAL 1992
LAWRENCE A. LOEB JOINS NEORX SCIENTIFIC ADVISORY BOARD
NEORX NAMES BIOTECHNOLOGY VETERAN FRED CRAVES CHAIRMAN OF BOARD OF DIRECTORS
NEORX DIVIDEND NOTICE
NEORX RECEIVES FDA CLEARANCE FOR AVICIDIN STUDY

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters